An Open-label, Single-arm, Phase 3 Study of Carfilzomib in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma in China
Phase of Trial: Phase III
Latest Information Update: 08 Oct 2017
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Amgen
- 11 May 2017 Planned End Date changed from 2 Feb 2021 to 14 May 2021.
- 11 May 2017 Planned primary completion date changed from 30 Sep 2018 to 8 Jan 2019.
- 28 Apr 2017 Status changed from not yet recruiting to recruiting.